Nevertheless, the first peptidic GLP1R agonist to be used as a drug was approved by FDA in 2005 (exenatide—Byetta) [26] and still the number of small-molecule non-peptidic compounds targeting incretin hormone receptors to treat diabetes and obesity is extremely small [28]. The gene discussed is GLP1R; the disease is diabetes mellitus.